Advances in nanotechnology are being applied in the development of novel
therapeutics that may address several shortcomings of conventional small molecule
drugs and may facilitate the realization of personalized medicine. Interestingly, nanoparticle
drug candidates often represent multiplexed formulations (e.g. drug, targeting moiety,
and nanoparticle scaffold material). By tailoring the chemistry and identity of variable
nanoparticle constituents, it is possible to achieve targeted delivery, decreased side
effects, and prepare formulations of unstable (e.g. siRNA) and/or highly toxic drugs.
With these benefits arise new challenges in all aspects of regulated drug development
and testing. In this review, we provide an up to date snapshot of silver nanomedicines
either currently approved by the FDA or other regulatory bodies.